Liposome Drug Delivery Market size was over USD 5.46 Billion in 2023 and is likely to exceed USD 17.14 Billion by the end of 2036, growing at over 9.2% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of liposome drug delivery is evaluated at USD 5.91 Billion. The growth of this market can be attributed to the growing demand for effective and efficient therapeutics considering the growing cases of chronic disease all over the world. As a result, drugs are encapsulated into liposomes for effective delivery. According to World Health Organization, 41 million people lose their life owing to chronic disease every year which is equivalent to 74% of death globally.
Increasing advances in liposomal drug delivery methods owing to new investments and ongoing R&D activities, product launches, mergers and acquisitions, and collaborations among major market players, are driving the growth of liposomal drug delivery expected to drive further growth of the market.
Moreover, various government authorities have been seen offering funds and investments for the research and development activities of the liposome drug delivery market. For instance, in 2019, the NIH awarded researchers at the University of Massachusetts Amherst a USD 1.7 million grant to develop new liposome-based vaccine delivery systems.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
9.2% |
|
Base Year Market Size (2023) |
USD 5.46 Billion |
|
Forecast Year Market Size (2036) |
USD 17.14 Billion |
|
Regional Scope |
|
Application (Fungal Diseases, Pain Management, Cancer Therapy, Viral Vaccines, Photodynamic Therapy)
The cancer therapy segment in the liposome drug delivery market is anticipated to hold the largest revenue share of 41% by the end of 2036. This can be attributed to the high prevalence of cancer and the growing demand for advanced therapeutics. As cancer is one of the diseases which attracts more attention from the R&D owing to its high prevalence and seriousness, this segment is anticipated to grow in the upcoming times. According to a report, there were approximately 19.3 million new cancer diagnoses worldwide in 2020, with breast cancer being the most common cancer, followed by lung cancer.
Product (Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B)
The liposomal doxorubicin segment is anticipated to hold 38% share of the global liposome drug delivery market by the end of 2036. This segment includes liposomes that are used to deliver the chemotherapy drug doxorubicin. Liposomal doxorubicin is effective in treating certain types of cancer, such as ovarian and breast cancer which is further expected to contribute to the growth of the segment over the coming decades.
Our in-depth analysis of the global market includes the following segments:
|
Product |
|
|
Technology |
|
|
Application |
|
North American Market Forecast
The liposome drug delivery market in North America is projected to garner the largest revenue of 45% by the end of 2036. The growth of the market in the region can primarily be attributed to the increasing prevalence of cancer in the region, followed by the surge in government initiatives that promote research and development for cancer drugs and drug delivery systems. According to the statistics by the National Cancer Institute (NCI), in the year 2020, the new cases of cancer that were expected to be diagnosed in the United States were about 1806590 cases. The statistics also stated that during the same year, 606520 people were expected to die as a result of the disease.
Europe Market Forecast
On the other hand, the liposome drug delivery market in Europe is projected to garner the second-largest revenue of 31% by the end of 2036. The market in Germany is projected to garner the second-largest revenue by the end of 2036 in Europe. The growing incidence of chronic illnesses including cancer and cardiovascular disease is driving the market. The rising demand for personalized medicine and the need for improved drug efficacy and safety are driving market growth. The market for liposome delivery in Europe is highly regulated with stringent safety and efficacy guidelines. Companies operating in the market must comply with these regulations to obtain approval for their products.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?